Relationship between autoantibodies to erythropoietin receptor and renal outcome in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis

被引:1
|
作者
Tran, Trang Thi Thu [1 ]
Hara, Akinori [2 ,3 ]
Kitagawa, Kiyoki [4 ]
Kitajima, Shinji [2 ]
Toyama, Tadashi [2 ]
Iwata, Yasunori [2 ]
Sakai, Norihiko [2 ]
Shimizu, Miho [2 ]
Kaneko, Shuichi [5 ]
Furuichi, Kengo [2 ]
Wada, Takashi [1 ,2 ]
机构
[1] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Dept Nephrol & Lab Med, Fac Med, 13-1 Takara Machi, Kanazawa, Ishikawa 9208641, Japan
[2] Kanazawa Univ Hosp, Div Nephrol, Kanazawa, Ishikawa, Japan
[3] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Dept Environm & Prevent Med, Fac Med, Kanazawa, Ishikawa, Japan
[4] Natl Hosp Org Kanazawa Med Ctr, Div Nephrol, Kanazawa, Ishikawa, Japan
[5] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Dept Dis Control & Homeostasis, Fac Med, Kanazawa, Ishikawa, Japan
基金
日本学术振兴会;
关键词
Anti-neutrophil cytoplasmic antibody; vasculitis; prognosis; erythropoietin receptor; autoantibody; SYSTEMIC-LUPUS-ERYTHEMATOSUS; ANEMIA;
D O I
10.1080/1354750X.2020.1727014
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Purpose: We examined the relationship between autoantibodies to erythropoietin receptor (EPOR) and renal outcome in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Materials and methods: Sixty-three Japanese patients with AAV were enrolled and followed for a median of 31.4 months. Patients were screened for serum anti-EPOR antibodies using an enzyme-linked immunosorbent assay. Associations of anti-EPOR antibodies with clinical parameters were analyzed using logistic-regression models. Results: Anti-EPOR antibodies were detected in 7 (11%) of the 63 patients, and levels of the antibodies decreased with immunosuppressive therapy. The presence of anti-EPOR antibodies was associated with a higher Birmingham vasculitis activity score. In addition, anti-EPOR antibodies were more frequently observed in patients with renal outcomes, which was defined as a sustained 50% reduction in the estimated glomerular filtration rate from baseline, than in those without. Multiple logistic regression analysis revealed that presence of anti-EPOR antibodies, as well as age at disease onset, were as risk factors for the renal outcome. Conclusion: Anti-EPOR antibodies were associated with the progression of renal dysfunction in patients with AAV.
引用
收藏
页码:194 / 200
页数:7
相关论文
共 50 条
  • [21] Application of biological agents in the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis
    Liu, Weijun
    Tian, Guanyuan
    Chen, Chao
    Zhang, Mingying
    Chen, Zhanmao
    Chen, Tietao
    Lin, Zhibin
    Wu, Wuzhong
    Wu, Yiqaing
    Wu, Kefei
    Liu, Qinghua
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [22] Ectopic Relapse of Anti-neutrophil Cytoplasmic Antibody-associated Pituitary Vasculitis with No Elevation of Anti-neutrophil Cytoplasmic Antibodies after Renal Remission
    Muto, Reiko
    Inagaki, Koji
    Sato, Naokazu
    Sameshima, Tetsuro
    Nagakura, Yuka
    Baba, Satoshi
    Kato, Noritoshi
    Maruyama, Shoichi
    Akahori, Toshiyuki
    INTERNAL MEDICINE, 2020, 59 (24) : 3187 - 3193
  • [23] Clinicopathological features of neuropathy in anti-neutrophil cytoplasmic antibody-associated vasculitis
    Koike, Haruki
    Sobue, Gen
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2013, 17 (05) : 683 - 685
  • [24] A case of anti-neutrophil cytoplasmic antibody-associated vasculitis masquerading as Sjogren syndrome
    Pillay, S. Sujitha
    Nune, Arvind
    Manzo, Ciro
    Barman, Bhupen
    Raza, Hasnain
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2023, 26 (12) : 2555 - 2558
  • [25] Anti-neutrophil cytoplasmic antibody-associated vasculitis: prevalence, treatment, and outcomes
    Lei Shi
    Rheumatology International, 2017, 37 : 1779 - 1788
  • [26] Anti-neutrophil cytoplasmic antibody-associated vasculitis: prevalence, treatment, and outcomes
    Shi, Lei
    RHEUMATOLOGY INTERNATIONAL, 2017, 37 (11) : 1779 - 1788
  • [27] Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis
    Basu, Neil
    McClean, Andrew
    Harper, Lorraine
    Amft, Esther N.
    Dhaun, Neeraj
    Luqmani, Raashid A.
    Little, Mark A.
    Jayne, David R. W.
    Flossmann, Oliver
    McLaren, John
    Kumar, Vinod
    Erwig, Lars P.
    Reid, David M.
    Macfarlane, Gary J.
    Jones, Gareth T.
    RHEUMATOLOGY, 2014, 53 (05) : 953 - 956
  • [28] Clinicopathological features of neuropathy in anti-neutrophil cytoplasmic antibody-associated vasculitis
    Haruki Koike
    Gen Sobue
    Clinical and Experimental Nephrology, 2013, 17 : 683 - 685
  • [29] Slowly progressive anti-neutrophil cytoplasmic antibody-associated renal vasculitis: clinico-pathological characterization and outcome
    Trivioli, Giorgio
    Gopaluni, Seerapani
    Urban, Maria L.
    Gianfreda, Davide
    Cassia, Matthias A.
    Vercelloni, Paolo G.
    Calatroni, Marta
    Bettiol, Alessandra
    Esposito, Pasquale
    Murtas, Corrado
    Alberici, Federico
    Maritati, Federica
    Manenti, Lucio
    Palmisano, Alessandra
    Emmi, Giacomo
    Romagnani, Paola
    Moroni, Gabriella
    Gregorini, Gina
    Sinico, Renato A.
    Jayne, David R. W.
    Vaglio, Augusto
    CLINICAL KIDNEY JOURNAL, 2021, 14 (01) : 332 - 340
  • [30] Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Large Vessel Vasculitis and Kawasaki Disease in Japan
    Kobayashi, Shigeto
    Fujimoto, Shouichi
    Takahashi, Kei
    Suzuki, Kazuo
    KIDNEY & BLOOD PRESSURE RESEARCH, 2010, 33 (06) : 442 - 455